Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00455871
Status:
UNKNOWN
Last Update Posted:
2008-05-09
First Post:
2007-04-02
Brief Title:
Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD
Sponsor:
Barnes Retina Institute
Organization:
Barnes Retina Institute
Study Overview
Official Title:
An Open-Label Single-Site Comparative Pilot Study of the Treatment Effects of Combination Therapy of Lucentis Ranibizumab Plus Reduced Fluence Photodynamic Therapy With Visudyne in Patients With Exudative Age-Related Macular Degeneration AMD
Status:
UNKNOWN
Status Verified Date:
2008-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the benefits if any of combination therapy with Lucentis plus reduced fluence photodynamic therapy with Visudyne
Detailed Description:
The study will have two treatment groups Each group will receive intravitreal injections injection of medication in the jelly-like part of the back of the eye One group Group1 of approximately 15 patients will receive 05 mg of Lucentis followed by reduced fluence Photodynamic Therapy PDT with Visudyne 1-2 weeks later The other group Group 2 of approximately 15 patients will receive 05 mg of Lucentis followed by Photodynamic Therapy with Visudyne on the same day patients will be assigned at random to receive one of the two treatments arms in the study The dose received at the first injection will be the same dose received throughout the study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCT00455871 | None | None | None |